Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Double Blinded Trial of Immune-Based Therapy With a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]

NCT07383441 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT07383441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07383441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Double Blinded Trial of Immune-Based Therapy With a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 3
Overall status
Recruiting
Start date
June 5, 2026
Completion date
January 31, 2034
Enrollment
718 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

advanced clear cell renal cell carcinoma, metastatic clear cell renal cell carcinoma, stage iii renal cell cancer ajcc v8, stage iv renal cell cancer ajcc v8